Curian Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Curian Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-16,051	Closed	-$348K	–	426
2015 Q4	$348K	Sell	16,051 -26,168	-62%	-$509K	0.03%	354
2015 Q3	$837K	Sell	42,219 -17,218	-29%	-$544K	0.02%	401
2015 Q2	$2.06M	Buy	59,437 +203	+0.3%	+$6.2K	0.03%	319
2015 Q1	$1.54M	Buy	59,234 +621	+1%	+$11.4K	0.03%	381
2014 Q4	$756K	Buy	+58,613	New	+$734K	0.01%	506

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Curian Capital's HZNP Position: Q1 2016 in Review

Curian Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2016, closing a stake of 16,051 shares — an estimated $348K sold.

Curian Capital first reported a position in HZNP in Q4 2014 and held it in 5 quarters. The position peaked at $2.06M in Q2 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Curian Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2016 after selling out during the quarter.
Curian Capital sold 16,051 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $348K.
Curian Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 5 quarters.
Curian Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.06M in Q2 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.